Top

6550--Notice of Intent to Sole Source Award for Blood Bank Analyzer and Reagents (520 0009)

Active

36C25622Q1413Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Department of Veterans Affairs plans to award a sole source firm-fixed price contract to Ortho-Clinical Diagnostics Inc. for the supply of red blood cell reagents needed at the Gulf Coast Veterans Health Care System in Biloxi, Mississippi. This one-year contract, starting October 1, 2022, is intended to ensure the proper testing, typing, and supply of blood and blood products used throughout the medical center. The reagents are required for use with the Ortho Clinical Micro Typing System Workstations, proprietary instruments owned and installed by the facility, which are FDA approved and require these specific reagents to function correctly. No alternate reagents are compatible or approved for use with this equipment, underscoring the justification for a sole source award under FAR 13.106-1(b). The reagents to be supplied include several specific products such as affirmagen, coombs control, a2 cells, resolve panels, and various Surgiscreen formulations, in quantities ranging from 13 to 28 units each. While this notice is not a solicitation for quotes or proposals, interested parties are invited to submit capability documentation including authorized distributor letters, product origin, company size, and SAM.gov registration status. This information will assist the government in determining whether to pursue a competitive procurement in the future. All responses and questions must be directed via email to the designated Contract Specialist by the specified deadline, with the government not liable for any costs associated with submissions.

General Info

One-year sole source contract to Ortho-Clinical for red blood cell reagents at Gulf Coast VA.

Agency

Department Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Set-Aside

NONE

Documents

Notice of Intent to Sole Source Award for Blood Bank Analyzer and Reagents 36C25622Q1413

notice-of-intent

Low

Notice+of+Intent+PDF+090122+Ortho+Clinical.pdf

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PostedSep 1

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)

Contacts1 person available

OfficeRIDGELAND, MS, 39157, USA

Organization / AgencyDepartment Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)

Office AddressRIDGELAND, MS, 39157, USA

Contacts

Mari GibsonContract Specialist

contact@example.gov

+1 (555) 000-0000

Full Description

INTENT TO SOLE SOURCE The Department of Veterans Affairs hereby submits a notice of intent to award a sole source firm-fixed price contract for red blood cell reagents to Ortho-Clinical Diagnostics Inc. for the Gulf Coast Veterans Health Care System, Biloxi, Mississippi 39531. The reagents will be used to properly test, type, and supply blood and blood products throughout the Medical Center. The anticipated award will be for one-year effective October 1, 2022. The NAICS code for this requirement is 325413 and the small business size standard is 1,250 employees. The anticipated sole source award is in accordance with FAR13.106-1(b). A single source justification has been prepared. The facility owns and has installed the Ortho Clinical Micro Typing System Workstations, which are used to perform the blood cell tests. The instruments are proprietary to Ortho Clinical Diagnostics, Inc. The systems and reagents are FDA approved to work in unison to provide the patient test performed by the lab department. No other reagents are compatible nor approved to be performed on this equipment. The reagents include the following: 0.8% AFFIRMAGEN (A1, B) COOMBS CONTROL A2 CELLS 3% RESOLVE PANEL C, AB ID, SOLN,3ML,0.8% RESOLVE PANEL A, AB ID, SOLN,3ML,0.8% 0.8% SURGISCREEN (1,2,3) ortho confidence system 3%SURGISCREEN (719100) Stock # Line Description Quantity Unit 719210 1 affirmagen 28 EA 719810 2 coombs control 13 EA 719310 3 a2 cells 13 EA 719410 4 resolve panel c 15 EA 6902317 5 0.8 % resolve A. 15 EA 6902316 6 0.8% surigscreen 28 EA 6902096 7 ortho confidence system 14 EA 719100 8 3%surgiscreen 28 EA This is NOT a request for quotes or proposals. However, all interested parties are encouraged to submit documentation demonstrating their capabilities to satisfy this requirement. The capabilities should include an authorized distributor letter, the country of origin of the products, the companies size status and the company must be registered in SAM.gov at the time of response. The determination not to compete this requirement is solely within the discretion of the Government. Information received will normally be considered for the purposes of determining whether to conduct a competitive procurement. The Government will not be responsible for any costs incurred by responding to this notice. Only emailed responses will be considered. All questions, responses, or comments to this Notice of Intent should be directed to Contract Specialist, Mari Gibson at contact@example.gov no later than September 9, 2022, at 10:00 AM CST. Please indicate in the subject line of your email: Notice of Intent - 36C24722Q1413, Blood Cell Reagents.